Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07037888

Efficacy of Ketorolac for Postoperative Pain Management in Hip Arthroscopy

The goal of this clinical trial is to learn whether the medication ketorolac can help manage pain after hip arthroscopy as well or better than the standard opioid-based pain medications. This study focuses on adult patients (over 18 years old) undergoing hip arthroscopy at Henry Ford Health System in Detroit, Michigan. Both men and women are included, and all participants must be able to consent and communicate in English.

The main questions it aims to answer are:

Can ketorolac help control pain as effectively or better than opioids after hip arthroscopy?

Will ketorolac use reduce the amount of opioid medication needed after surgery?

Researchers will compare the group receiving ketorolac to the group receiving standard opioid pain medications to see if ketorolac reduces pain and opioid use after surgery.

Participants will:

Be randomly assigned to one of two groups:

The control group, which receives the current standard pain management protocol (hydrocodone-acetaminophen and diazepam)

The experimental group, which receives the same protocol plus ketorolac and a stomach-protecting medication (omeprazole)

Receive their assigned pain medications after hip arthroscopy

Be asked to:

Take the prescribed medications after discharge

Complete a pain journal for 5 days following surgery, documenting pain levels and any side effects

Complete follow-up surveys and assessments at 2 weeks, 6 weeks, and 3 months after surgery

The main measurement researchers will use is the Visual Analog Scale (VAS) for pain on post-operative day 4. Additional measures include how many narcotic pills are used and results from PROMIS physical function and pain interference scores.

The hope is that ketorolac will provide equal or better pain control without the risks of addiction and side effects associated with opioid medications. If successful, this approach could offer a safer alternative for managing pain after hip arthroscopy. Participants may personally benefit by having effective pain relief with fewer risks, and future patients could benefit from improved pain management options.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–89 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Henry Ford Health

Detroit, Michigan, 48202, United States

Location status: Recruiting

Location contact

Jhamal Wallace

CONTACT

[email protected]

(800) 436-7936

Michael Gaudiani

CONTACT

[email protected]

Michael Gaudiani

SUB_INVESTIGATOR

Thomas Lynch

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients undergoing hip arthroscopy over the age of 18 with Dr. T. Sean Lynch
  • Diagnosis of femoroacetabular impingement (FAI)

Exclusion criteria

  • Patients with inability to consent and/or do not speak English
  • Patients with conditions contraindicated with NSAIDs (medication allergy, peptic ulcer disease, bleeding diathesis, and renal disease)
  • Patients with history of drug and alcohol use disorder
  • Patients with chronic analgesia (filled two opioid prescriptions within 6 months of the surgery)
  • Patients with psychotropic medication usage
  • Patients who take pentoxifylline, probonecid, aspirin, and/or NSAIDs who cannot stop taking it for the study
  • Patients who are not discharged same day after surgery

Treatment and study plan

Ketorolac

Drug

IV ketorolac intraoperative loading dose Ketorolac 10mg 1 tablet q6hrs to start on POD0

Control (Standard treatment)

Drug

hydrocodone-acetaminophen 5mg/325mg 1 tablet q6hrs PRN to start on POD0 30 tablets

Omeprazole

Drug

20 mg qd

Primary outcomes

  1. Visual Analogue Scale (VAS)

    Time frame: 5 days

    A validated tool used to help a person rate the intensity of certain sensations and feelings, such as pain. The visual analog scale for pain is a straight line with the far-left end meaning no pain and the far-right end meaning the worst pain imaginable. A patient marks a point on the line that matches the amount of pain he or she feels. It may be used to help choose the right dose of pain medicine.

Secondary outcomes

  1. PROMOIS- PF

    Time frame: 2 weeks, 6 weeks, 3 months

    This is a standardized patient-reported outcome measure that assesses an individual's self-reported capability to perform physical activities, including both basic activities of daily living (ADLs) and instrumental activities of daily living (IADLs). It utilizes a T-score scale, mean = 50, standard deviation = 10, and higher scores indicate greater physical function.

  2. PROMOIS- PI

    Time frame: 2 weeks, 6 weeks, 3 months

    a patient-reported outcome measure that assesses the extent to which pain hinders a person's engagement in various activities. It utilizes a T-score scale, mean = 50, standard deviation = 10, and higher scores indicate greater interference from pain.

Sponsors and collaborators

Lead sponsor

Henry Ford Health System

Other

Registry information

Official study title

Efficacy of Ketorolac for Postoperative Pain Management in Hip Arthroscopy: A Prospective, Randomized, Clinical Trial

Important dates

Study start
2023
Primary completion
2026
Study completion
2026
First posted
Jun 26, 2025
Registry last updated
Jun 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.